French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Sanofi ( NASDAQ: SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which typically runs ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season  Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early ...

French pharma major Sanofi (Euronext: SAN) has started early global shipments of its monoclonal antibody Beyfortus ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 ...

Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...